Quarterly report pursuant to Section 13 or 15(d)

SCHEDULE OF SEGMENT INFORMATION (Details)

v3.24.1.1.u2
SCHEDULE OF SEGMENT INFORMATION (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Apr. 30, 2024
Apr. 30, 2023
Apr. 30, 2024
Apr. 30, 2023
Oct. 31, 2023
Segment Reporting Information [Line Items]          
Net loss $ (3,180) $ (2,307) $ (6,470) $ (4,661)  
Total operating costs and expenses 3,467 2,770 7,076 5,326  
Less non-cash stock-based compensation (1,260) (1,227) (2,520) (2,290)  
Operating costs and expenses excluding non-cash share based compensation 2,207 1,543 4,556 3,036  
Total assets 24,355   24,355   $ 25,522
CAR-T Therapeutics [Member]          
Segment Reporting Information [Line Items]          
Net loss (1,444) (997) (2,970) (1,908)  
Operating costs and expenses excluding non-cash share based compensation 1,026 620 2,154 1,218  
Total assets 11,314   11,314   7,523
Cancer Vaccines [Member]          
Segment Reporting Information [Line Items]          
Net loss (1,713) (913) (3,469) (1,871)  
Operating costs and expenses excluding non-cash share based compensation 1,160 523 2,373 1,111  
Total assets 12,778   12,778   17,215
Other [Member]          
Segment Reporting Information [Line Items]          
Net loss (23) (397) (31) (882)  
Operating costs and expenses excluding non-cash share based compensation 21 $ 400 29 $ 707  
Total assets $ 263   $ 263   $ 784